Numerous placebo controlled studies of women, including NSABP P 1 1998, MORE 1 1999, and CORE 2004, have demonstrated a reduction in the risk of breast cancer with selective estrogen receptor modulators SERMs tamoxifen and raloxifene <a href=http://cialis